Prevymis (letermovir) / Merck (MSD), AiCuris - LARVOL DELTA

Influence of a 3-month letermovir treatment on gut permeability and inflammation in people living with HIV on antiretroviral therapy (EACS 2025) - No abstract available

Human Immunodeficiency Virus • Infectious Disease

Asymptomatic CMV Suppression with Letermovir Reduces Plasma Secondary Bile Acid Levels in Individuals with HIV on Long-term Antiretroviral Therapy: ACTG Study A5383 (EACS 2025) - No abstract available

Clinical • Human Immunodeficiency Virus • Infectious Disease

Impact of letermovir on Cytomegalovirus-specific T-cells reconstitution after allogeneic hematopoietic stem cell transplantation in the post-transplant cyclophosphamide era. (PubMed, Haematologica) - "Not available."

Journal • Bone Marrow Transplantation • Cytomegalovirus Infection • Transplantation

FURTHER EVIDENCE SUPPORTING THE USE OF LETERMOVIR FOR CMV PROPHYLAXIS - IT'S NOT ONLY LEUKOPENIA. (PubMed, Am J Transplant) - No abstract available

Journal • Hematological Disorders • Leukopenia • Transplantation

Toxicity and Adverse Outcomes of Letermovir vs. Valganciclovir Cytomegalovirus (CMV) Prophylaxis in Lung Transplantation (IDWeek 2025) - No abstract available

Adverse events • Cytomegalovirus Infection • Infectious Disease

A Historical Controlled, Single Center Open Label Pilot Study Comparing the Effectiveness and Tolerability of De Novo Initiation of Letermovir versus Valganciclovir for Cytomegalovirus Prophylaxis in African American Kidney Transplant Recipients (WTC 2025) - P3 | "Preliminary results suggest LET is an effective, well-tolerated alternative to VGC for CMV prophylaxis in high-risk AA KTRs. LET was associated with lower breakthrough CMV and leukopenia while maintaining comparable survival rates. Further follow-up is ongoing to confirm these initial findings."

Clinical • Cytomegalovirus Infection • Hematological Disorders • Immunology • Infectious Disease • Leukopenia • Septic Shock • Transplant Rejection • Transplantation

VALET-CMV: Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant (clinicaltrials.gov) - P2/3 | N=150 | Recruiting | Sponsor: Columbia University

New P2/3 trial • Cytomegalovirus Infection • Infectious Disease • Neutropenia • Transplant Rejection • Transplantation

Impact of kidney function on 200 days of antiviral prophylaxis for cytomegalovirus disease in CMV-seronegative recipients of CMV-seropositive donor kidneys Post hoc analysis of a randomized, phase 3 trial of letermovir versus valganciclovir prophylaxis. (PubMed, Am J Transplant) - P3 | "Adult CMV D+R- KTRs were randomized (1:1) post-transplant to letermovir 480 mg (with acyclovir and valganciclovir placebo) or valganciclovir 900 mg (with acyclovir and letermovir placebos) daily for 28-weeks (NCT03443869). In CMV D+R- KTRs, letermovir prophylaxis was associated with less CMV DNAemia compared to valganciclovir in participants with low kidney function during the 200-day prophylaxis period. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov: NCT03443869, EudraCT: 2017-001055-30."

Journal • P3 data • Retrospective data • Cytomegalovirus Infection • Infectious Disease • Transplantation

Probable reactivation from latency of multi-drug resistant cytomegalovirus in a lung transplant recipient: a case report. (PubMed, Am J Transplant) - "Whether ganciclovir-resistant cytomegalovirus (ganR-CMV) can establish latency and reactivate absent any selective drug pressure is unknown and has implications for selecting empiric antiviral therapy in patients with prior ganR-CMV...Foscarnet therapy led to CMV DNAemia clearance and disease resolution...Valganciclovir was given for three days post-transplant, then switched to letermovir prophylaxis for three months...These unusual circumstances suggest establishment of latency with an antiviral-resistant CMV strain and subsequent late reactivation during augmented immunosuppression at the time of a new kidney transplant. Genotypic antiviral resistance testing should be considered even in cases of remote, resolved ganR-CMV infection to guide appropriate antiviral therapy."

Journal • Cytomegalovirus Infection • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Solid Organ Transplantation • Transplantation

Clinical Outcome differences in Kidney Transplant Patients Receiving Letermovir Versus Valganciclovir for CMV Prophylaxis (IDWeek 2025) - No abstract available

Clinical • Clinical data • Infectious Disease

OPTIMUS-EL: Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy (clinicaltrials.gov) - P2 | N=40 | Not yet recruiting | Sponsor: Seoul National University Hospital | Initiation date: May 2025 ➔ Sep 2025

Trial initiation date • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Oncology

Real-World Use of Letermovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients (IDWeek 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Cytomegalovirus Infection • Infectious Disease

Letermovir use for CMV prophylaxis in lung transplant recipients : A single center experience (IDWeek 2025) - No abstract available

Clinical • Infectious Disease

Letermovir as CMV Prophylaxis in Liver Transplant Recipients (IDWeek 2025) - No abstract available

Clinical • Cytomegalovirus Infection • Infectious Disease

Letermovir Prophylaxis for CMV Infection in Pediatric Transplant Recipients: 2025 Updates (IDWeek 2025) - No abstract available

Clinical • Cytomegalovirus Infection • Infectious Disease

247 - It's a Small World After All: Prevention and Treatment in the Expanding World of Pediatric Immunocompromised Hosts (IDWeek 2025) - "Learning Objectives: At the conclusion of this session, participants will be able to: discuss current approaches to infection prophylaxis in neutropenic hosts and their limitations and solutions; describe how antimicrobial use can be optimized in pediatric patients with fever and neutropenia; describe the evidence-based use of letermovir in pediatric transplant recipients."

Clinical • Infectious Disease

An Update on the Efficacy and Safety Profile of 200-day Prevymis Therapy and Q&A (ICBMT 2025) - "Sponsored by MSD Merck (MSD)"

Clinical

Post-HSCT Viral Management: Strategies Beyond the Guidelines (ICBMT 2025) - "Despite the integration of Letermovir into standard prophylaxis regimens, breakthrough infections persist, especially beyond D+100, with Korean real - world data showing clinically significant CMV infection (csCMVi) rates rising from 9.5% at 14 weeks to 29.4% by 24 weeks...We present a real -world case of ganciclovir -resistant CMV harbouring the UL97 H520Q mutation, which necessitated sequential therapy with foscarnet and later maribavir...Prophylaxis with oral acyclovir for up to one year reduces early incidence but carries rebound risks and is limited by long -term toxicity and antiviral resistance. The advent of the recombinant zoster vaccine (RZV; Shingrix) offers a promising preventive strategy, particularly in the 6 –24 month window post -transplant...Optimal outcomes require a personalised, adaptive strategy that incorporates novel therapeutics, surveillance tools, and host factors. Through real -world evidence and clinical insight, this lec ture aims to equip..."

Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Malignancies • Herpes Zoster • Immunology • Infectious Disease • Varicella Zoster

Impact of Letermovir Prophylaxis on the Pattern of CMV Events and Its Association with Relapse in Allogenic HSCT Recipients for Myelodysplastic Syndromes (ICBMT 2025) - No abstract available

Bone Marrow Transplantation • Hematological Malignancies • Myelodysplastic Syndrome

The interplay between Epstein-Barr Virus and Cytomegalovirus reactivation following allogeneic hematopoietic cell transplantation in the era of primary CMV prophylaxis. (PubMed, Clin Microbiol Infect) - "EBV reactivation had no apparent correlation with letermovir prophylaxis, was associated with previous CMV reactivation, and had no significant impact on mortality."

Journal • Acute Myelogenous Leukemia • Chronic Myelomonocytic Leukemia • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Oncology • Transplantation

Cytomegalovirus prophylaxis with letermovir in pediatric (birth to <18 years of age) hematopoietic cell transplant recipients: pharmacokinetics, efficacy, and safety results of a Phase 2b study. (PubMed, Antimicrob Agents Chemother) - P2 | "In AG3, the initial cohort (letermovir with cyclosporin A) achieved exposures trending lower than the median exposure target; the letermovir dose was increased for the remaining participants. At exposures achieved, letermovir was efficacious and safe in preventing clinically significant CMV infection in pediatric allogeneic HCT recipients. The observed concentration data informed a pediatric PopPK model to optimize final letermovir dose recommendations in this population.CLINICAL TRIALSThis study is registered with ClinicalTrials.gov as NCT03940586."

Journal • P2b data • PK/PD data • Bone Marrow Transplantation • Cytomegalovirus Infection • Infectious Disease • Pediatrics • Transplantation

Pharmacokinetics of Oral Letermovir in Adults With End-Stage Kidney Disease With or Without Haemodialysis (clinicaltrials.gov) - P1 | N=20 | Not yet recruiting | Sponsor: Jason A Roberts

New P1 trial • Chronic Kidney Disease • Nephrology • Renal Disease

A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection (clinicaltrials.gov) - P2 | N=102 | Completed | Sponsor: Memorial Sloan Kettering Cancer Center | Active, not recruiting ➔ Completed

Trial completion • Bone Marrow Transplantation • Cytomegalovirus Infection • Infectious Disease • Transplantation

Impact of CMV-Specific Immune Reconstitution at the End of Letermovir Prophylaxis on the Development of Late Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Recipients (INMUNOEND) (clinicaltrials.gov) - P=N/A | N=123 | Not yet recruiting | Sponsor: Maimónides Biomedical Research Institute of Córdoba | Initiation date: Mar 2025 ➔ Aug 2025

Trial initiation date • Bone Marrow Transplantation • Cytomegalovirus Infection • Infectious Disease • Transplantation

A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection (clinicaltrials.gov) - P2 | N=102 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial primary completion date: Jul 2025 ➔ Aug 2024

Trial primary completion date • Bone Marrow Transplantation • Cytomegalovirus Infection • Infectious Disease • Transplantation